GI Cancers

FDA Grants Fast Track Designation to DKN-01 in Gastric/GEJ Adenocarcinoma

September 24, 2020

The FDA has granted a Fast Track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors express the protein DKK1, following disease progression on or after prior treatment with fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate, human epidermal receptor growth factor/neu-targeted therapy.

Survival Significantly Improved With Frontline Nivolumab Combo in Gastric/GEJ Cancer and Esophageal Adenocarcinoma

September 21, 2020

Frontline nivolumab plus chemotherapy induced a statistically significant survival benefit compared with chemotherapy alone in patients with newly diagnosed PD-L1–positive advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

Pembrolizumab Plus Chemotherapy Enters Frontline Treatment Landscape of Advanced Esophageal Cancer

September 21, 2020

In the phase 3 KEYNOTE-590 clinical trial, frontline pembrolizumab plus chemotherapy demonstrated a significant improvement in overall survival, progression-free survival, and objective response rates versus chemotherapy only in patients with locally advanced unresectable or metastatic esophageal cancer, result presented during the 2020 ESMO Virtual Congress show.

Nivolumab Plus Chemotherapy Extends PFS With Durable Responses in Gastric/GEJ Cancers

September 21, 2020

In the phase 3 ATTRACTION-4 study, nivolumab added to chemotherapy led to a statistically significant improvement in progression-free survival and induced higher overall response rates in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer, according to results presented during the 2020 ESMO Virtual Congress.

Significant PFS Benefit Observed With Surufatinib in Pancreatic NETs

September 21, 2020

A statistically significant and clinically meaningful improvement in progression-free survival was observed with the use of surufatinib compared with placebo in patients with advanced pancreatic neuroendocrine tumors, meeting the primary end point of the randomized phase 3 SANET-p study.

Lanreotide Autogel Dosed More Frequently Delays More Toxic Regimens in Pancreatic, Midgut NETs

September 19, 2020

For patients with progressive pancreatic or midgut neuroendocrine tumors, improvements in disease-free survival and progression-free survival were seen when the dosing of lanreotide Autogel was increased from 120 mg every 28 days to every 14 days. Data from the phase 2 CLARINET FORTE study suggest that this treatment option can delay switching to a more toxic treatment, which was presented at the 2020 ESMO Virtual Congress.

Promising Activity Seen With Dabrafenib Doublet in BRAF V600E+ Biliary Tract Cancer

September 18, 2020

The combination of dabrafenib and trametinib in patients with biliary tract cancer and BRAF V600E mutations demonstrated clinical activity and a manageable safety profile, according to results from the phase 2 ROAR study.

Futibatinib Induces Durable Responses in FGFR2+ Intrahepatic Cholangiocarcinoma

September 18, 2020

Futibatinib demonstrated efficacy and tolerability when administered as treatment of patients with intrahepatic cholangiocarcinoma who harbor FGFR2 fusions/rearrangements, according to interim analysis results presented in a poster during the the European Society of Medical Oncology Virtual Congress 2020

Doctors Debate: Should Perioperative Treatment of GEJ/Gastric Cancer Include Radiotherapy?

August 24, 2020

During a debate at the 2020 Debates and Didactics in Hematology and Oncology Conference, Mehmet Akce, MD and Pretesh Patel, MD, argued their position on whether perioperative therapy for GEJ/gastric cancers should include radiation.

Promising Phase 3 Study of CPI-613 in Metastatic Pancreatic Cancer Achieves Target Enrollment Early

August 24, 2020

In an interview with Targeted Oncology, Philip A. Philip, MD, PhD, discussed the current therapeutic options for patients with metastatic pancreatic cancer and where CPI-613 may fit into this treatment landscape.